VEGFA and neoplasm: In the GL261-luc-GFP subcutaneous tumor model, anti-PD-L1 antibody-modified VEGF-siRNA LNPs significantly suppressed tumor growth compared to all other groups, maintaining smaller tumor volumes throughout the study period (p < 0.05; Figure 3).